Skip Content
Page Banner Image

Study of WVE-003 in Patients With Huntington’s Disease

Wave Life Sciences Ltd.

This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) – SNP3.


Formal Name
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease.

Study Type
Interventional (Clinical Trial)


Canadian Locations:


Location: University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2G3
Status: Recruiting

Principal Investigator: Oksana Suchowerky, MD


Location: The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Status: Recruiting

Principal Investigator: Tiago Mestre, MD, MsC


Location: Centre Hospitalier de l’Universite de Montreal
Montréal, Quebec, Canada, H2X019
Status: Recruiting

Principal Investigator: Dr. Sylvain Chouinard

Ages Eligible for Study: 25 Years to 60 Years (Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria

  • Presence of the A variant of SNP3 on the same allele as the pathogenic CAG triplet expansion
  • Ambulatory, male or female patients aged ≥25 to ≤60 years
  • Clinical diagnostic motor features of HD, defined as Unified Huntington’s Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4
  • UHDRS Total Functional Capacity Scores ≥9 and ≤13

Exclusion Criteria  (eligibility that would exclude you from this study)

  • Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years
  • Received any other study drug, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer, with the exception of the following:a. Received WVE-120101 or WVE-120102 within the last 3 months
  • Implantable CNS device that may interfere with ability to administer study drug via lumbar puncture or undergo MRI scan
  • Inability to undergo brain MRI (with or without sedation)
  • Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture


For more detailed information on this study and others and for the most recent updates, please go to is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

Back to map

We support those facing huntington disease
 Latest Blog


Have questions? Send us an email at:



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up

Copyright © Huntington Society of Canada. All Rights Reserved. Charitable Registration Number 11896 5516 RR0001